Targeting PCSK9 axis for castration-resistant prostate cancer recurrence suppression
靶向 PCSK9 轴抑制去势抵抗性前列腺癌复发
基本信息
- 批准号:10555260
- 负责人:
- 金额:$ 16.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdjuvantAdvocateAgonistAndrogen AntagonistsAndrogen ReceptorAndrogen SuppressionAspergillus fumigatusAutomobile DrivingBiological AvailabilityBlood specimenCancer PatientCancer RelapseCell Surface ReceptorsCellsCholesterolChromatographyChronicClinicalClinical PathologyDataDiseaseDoseDrug ControlsDrug KineticsExcisionFDA approvedFermentationFollicle Stimulating HormoneHistopathologyHumanImmunotherapyIndividualInterventionKDR geneLDL Cholesterol LipoproteinsLactamsLeadLinkLipidsLow Density Lipoprotein ReceptorLuteinizationMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMetastatic Prostate CancerMonoclonal AntibodiesMusNatural ProductsNeoadjuvant TherapyNeoplasm MetastasisNude MiceObesityOperative Surgical ProceduresOralOrganOutcomePECAM1 genePTK2 genePathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhenotypePremalignant CellPreventionPreventivePrimary NeoplasmProprotein ConvertasesProstatePublishingRecurrenceRecurrent Malignant NeoplasmRecurrent tumorRegimenResistanceResistance developmentRoleSafetySlideStagingStainsSubtilisinsSurvival RateSurvivorsTestingTestosteroneTissue MicroarrayValidationWestern Blottingalbino mouseangiogenesisanimal imagingcancer cellcancer clinical trialcancer recurrencecastration resistant prostate cancercell motilitychemotherapycholesterol biosynthesiscostdocetaxeleffective therapyenzalutamideextracellularfungushormone therapyhuman tissuehypercholesterolemiainhibitorknock-downmalignant breast neoplasmmenmicrobialmolecular sizemortalitymouse modelneoplastic cellnovelnovel therapeuticspaxillinpreclinical studypreventprospectiveprostate cancer cellprostate cancer metastasisprostate cancer preventionprostate cancer progressionprostate cancer survivorsprotein protein interactionreceptor expressionrelapse preventionselective androgen receptor modulatorserum PSAside effectsmall moleculetargeted treatmenttumoruptakevalidation studies
项目摘要
SUMMARY
Metastatic castration-resistant prostate cancer (mCRPC) is the most recurrent and, fatal
phenotype. mCRPC patients have poor recurrence-free and limited preventive options. The
natural product pseurotin A (PS) dually suppressed PCSK9 secretion and interaction with LDLR.
PS suppressed 94% of PC-3 PC recurrence in nude mice model. PS antimigratory activity
significantly reduced when PCSK9 knocked-down. The small molecular size of PS is
advantageous over the FDA-approved humanized PCSK9 mAbs acting intra- and extra-cellular
unlike the later which can act extracellular only, reflecting better potency. Recently, PCSK9
proved critical driver for prostate and several other cancers. Project central hypothesis is
targeting extra- and intracellular PCSK9 axis with the small molecule PCSK9 inhibitor
pseurotin A can effectively prevent mCRPC recurrences and therefore PS can be
developed as effective recurrence preventer in mCRPC survivors. Aim 1: Efficacy of PS to
prevent mCRPC recurrence in nude mice and PCSK9 validation as a pathogenesis marker in
human PC tissues microarray. Assessments will compare PS potency in wild and PCSK9-
knockdown CWR-R1ca cells in adjuvant (post-primary tumor excision) mode and after
neoadjuvant enzultamide- docetaxel regimen followed by primary tumor surgical excision in nude
mice models. Biomax human tissue microarray will be used to validate PCSK9 relevance in
human PC. Aim 2: Assess the PS safety and pharmacokinetics in Swiss albino mouse models.
Expected outcomes: Proposed studies entail PS validation as a novel targeted intervention for
mCRPC recurrences prevention. PCSK9 targeting is a novel therapeutic alternative for long-term
prevention of metastatic castration-resistant prostate cancer recurrence in prostate cancer
survivors.
摘要
转移性去势抵抗前列腺癌(MCRPC)是复发率最高、致死率最高的肿瘤。
表型。MCRPC患者无复发能力差,预防措施有限。这个
天然产物Pseurotin A(PS)对PCSK9的分泌和与LDLR的相互作用具有双重抑制作用。
PS对裸鼠模型中94%的PC-3PC复发有抑制作用。多糖硫酸酯抗迁移活性
当PCSK9被推倒时,显著减少。PS的小分子尺寸是
优于FDA批准的作用于细胞内外的人源化PCSK9单抗
与后者不同,后者只能作用于细胞外,反映出更好的效力。最近,PCSK9
事实证明,它是前列腺癌和其他几种癌症的关键驱动力。项目中心假设是
小分子PCSK9抑制剂靶向细胞内外PCSK9轴
Pseurotin A能有效防止mCRPC复发,因此PS可以
成为mCRPC存活者有效的复发预防药物。目标1:PS的疗效
PCSK9在裸鼠体内预防mCRPC复发及其作为发病机制标志物的验证
人PC组织微阵列。评估将比较野生和PCSK9中的PS效力-
在辅助(原发肿瘤切除后)模式下和之后击倒CWR-R1ca细胞
新辅助苯舒他胺-多西紫杉醇联合裸鼠原发肿瘤手术切除
小鼠模型。Biomax人体组织微阵列将用于验证PCSK9的相关性
人类个人电脑。目的2:评价PS在瑞士白化小鼠模型中的安全性和药代动力学。
预期结果:拟议的研究需要PS作为一种新的有针对性的干预措施
预防mCRPC复发。PCSK9靶向治疗是一种新的长期治疗方案
前列腺癌抗去势转移复发的预防
幸存者。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation.
- DOI:10.3390/md21040215
- 发表时间:2023-03-28
- 期刊:
- 影响因子:5.4
- 作者:
- 通讯作者:
The Tobacco β-Cembrenediol: A Prostate Cancer Recurrence Suppressor Lead and Prospective Scaffold via Modulation of Indoleamine 2,3-Dioxygenase and Tryptophan Dioxygenase.
烟草β-环甲基二醇:前列腺癌复发抑制铅和前瞻性支架,通过调节吲哚胺2,3-二氧酶和色氨酸二氧酶。
- DOI:10.3390/nu14071505
- 发表时间:2022-04-04
- 期刊:
- 影响因子:5.9
- 作者:Mudhish, Ethar A.;Siddique, Abu Bakar;Ebrahim, Hassan Y.;Abdelwahed, Khaldoun S.;King, Judy Ann;El Sayed, Khalid A.
- 通讯作者:El Sayed, Khalid A.
Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice.
- DOI:10.3390/molecules28031460
- 发表时间:2023-02-02
- 期刊:
- 影响因子:4.6
- 作者:McGehee, Oliver C.;Ebrahim, Hassan Y.;Rad, Ashkan H.;Abdelwahed, Khaldoun S.;Mudhish, Ethar A.;King, Judy A.;Helal, Iman E.;Meyer, Sharon A.;El Sayed, Khalid A.
- 通讯作者:El Sayed, Khalid A.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KHALID A EL SAYED其他文献
KHALID A EL SAYED的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KHALID A EL SAYED', 18)}}的其他基金
Targeting PCSK9 axis for castration-resistant prostate cancer recurrence suppression
靶向 PCSK9 轴抑制去势抵抗性前列腺癌复发
- 批准号:
10429627 - 财政年份:2022
- 资助金额:
$ 16.15万 - 项目类别:
Oleocanthal functional food products for breast cancer recurrence control
用于控制乳腺癌复发的油橄榄功能性食品
- 批准号:
10276305 - 财政年份:2020
- 资助金额:
$ 16.15万 - 项目类别:
Design of novel c-Met inhibitors inspired by olive phenolics
受橄榄酚类启发的新型 c-Met 抑制剂的设计
- 批准号:
8434417 - 财政年份:2013
- 资助金额:
$ 16.15万 - 项目类别:
MARINE NATURAL PRODUCTS AS ANTI-ANGIOGENIC AND ANTI-INVASIVE AGENTS
海洋天然产品作为抗血管生成和抗侵袭剂
- 批准号:
7959461 - 财政年份:2009
- 资助金额:
$ 16.15万 - 项目类别:
MARINE NATURAL PRODUCTS AS ANTI-ANGIOGENIC AND ANTI-INVASIVE AGENTS
海洋天然产品作为抗血管生成和抗侵袭剂
- 批准号:
7719997 - 财政年份:2008
- 资助金额:
$ 16.15万 - 项目类别:
MARINE NATURAL PRODUCTS AS ANTI-ANGIOGENIC AND ANTI-INVASIVE AGENTS
海洋天然产品作为抗血管生成和抗侵袭剂
- 批准号:
7609940 - 财政年份:2007
- 资助金额:
$ 16.15万 - 项目类别:
DEVELOPMENT OF MARINE MACROLIDES LATRUNCULINS AS ANGIOGENESIS MODULATORS
作为血管生成调节剂的海洋大环内酯 Latrunculins 的开发
- 批准号:
7381335 - 财政年份:2006
- 资助金额:
$ 16.15万 - 项目类别:
ANTICANCER AND ANTI-INFECTIVE METABILITES FOR SYMBIOTIC MARINE MICROORGANISMS
共生海洋微生物的抗癌和抗感染代谢物
- 批准号:
7381336 - 财政年份:2006
- 资助金额:
$ 16.15万 - 项目类别:
DEVELOPMENT OF THE MARINE MACROLIDES LATRUNCULINS
海洋大环内酯类 LATRUNCULINS 的开发
- 批准号:
6981539 - 财政年份:2003
- 资助金额:
$ 16.15万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别: